

Propanc Biopharma Inc
302/6 Butler Street
Camberwell, Victoria, 3124
Australia

FyoniBio GmbH
Robert-Roessle-Str. 10
13125 Berlin
Germany

Propanc and FyoniBio Join Forces to Establish and Validate a Pharmacokinetics Assay for Pancreatic Proenzyme Formulation

Press Release

Melbourne, Australia / Berlin, Germany — March 2026

Propanc, a biopharmaceutical company focused on developing novel treatments for chronic diseases, and **FyoniBio**, a German expert in clinical bioanalysis, are pleased to announce the execution of a service agreement to establish and validate a liquid chromatography-mass spectrometry (LC-MS) based pharmacokinetics assay for Propanc's lead product candidate, PRP. This assay is a critical step in supporting our upcoming Phase 1b First-In-Human study, enabling precise quantification of PRP and its analytes in patients with advanced solid tumors.

Combining Strengths with FyoniBio

FyoniBio, backed by over 15 years of expertise, offers broad analytical development capabilities under Good Clinical Laboratory Practice (GCLP) as well as in-depth Mass Spectrometry based analytics which will be employed in this project.

"FyoniBio is proud to bring our deep expertise in GCLP-compliant bioanalysis and advanced mass spectrometric technologies to this collaboration, ensuring robust and regulatory-ready assay development for Propanc's innovative protein formulation." said **Hans Baumeister**, Managing Director and Founder of FyoniBio.

"We are pleased to continue our ongoing partnership with FyoniBio and are confident they will deliver the results we need for our clinical bioanalysis of lead asset, PRP, in our Phase 1b, First-In Human study. The information generated will be pivotal to our clinical assessment during the upcoming study regarding PRP's effects for safety and tolerability, as well as efficacy signals in advanced cancer patients." said **James Nathanielsz**, CEO and Founder of Propanc.

About Propanc

Propanc Biopharma, Inc. (Nasdaq: PPCB) is developing a novel approach to preventing cancer recurrence and metastasis by targeting and eradicating cancer stem cells through proenzyme activation. The Company's lead product candidate, PRP, is designed to address the underlying drivers of cancer proliferation and spread.

Learn more at: <https://www.propanc.com/>

About Fyonibio

Fyonibio is a biologics service provider with over 15 years of scientific expertise and a proven track record of supporting more than 100 biologics projects for biotech and pharma companies worldwide. Trusted by partners whose products have reached clinical development in both FDA and EMA regions, Fyonibio offers a broad service portfolio covering the entire development chain — from cell line and process development to analytical characterization and clinical bioanalysis under GCLP.

Our team combines deep scientific understanding with flexibility and transparent communication to deliver tailored solutions that meet each project's specific needs. All services are performed under our ISO 9001–certified quality management system, ensuring full compliance with international ISO and ICH standards.

Learn more at: <https://www.fyonibio.com/>

Press Contacts

James NATHNIELSZ
Chief Executive Officer, Propanc Biopharma, Inc.
irteam@propanc.com

Abdullah KARACORLUOGLU
Business Development Manager, Fyonibio GmbH
abdullah.karacorluoglu@fyonibio.com